Sucampo Pharmaceuticals, Inc.(NASDAQ : SCMP)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||2.02%||159.26||0.7%||$1174.61m|
|MRK||Merck & Co., Inc.||3.30%||75.54||0.7%||$887.74m|
|BMY||Bristol-Myers Squibb Co.||1.89%||61.57||1.0%||$850.37m|
|LLY||Eli Lilly & Co.||1.60%||210.24||1.1%||$646.08m|
|KALV||KalVista Pharmaceuticals, Inc.||-0.76%||30.65||0.4%||$98.88m|
|NVO||Novo Nordisk A/S||-0.01%||69.60||0.1%||$91.35m|
|RPRX||Royalty Pharma Plc||5.62%||44.93||0.2%||$84.16m|
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products â€“ AMITIZA, its lead product, and RESCULA â€“ and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.